Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Peter Nightingale, Chim Lang, Dana Dawson, Michael Frenneaux

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

ABSTRACT  Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

Original languageEnglish
Pages (from-to)693-698
Number of pages6
JournalFuture cardiology
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 2014

    Fingerprint

Cite this

Singh, S., Beadle, R., Cameron, D., Rudd, A., Bruce, M., Jagpal, B., ... Frenneaux, M. (2014). Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. Future cardiology, 10(6), 693-698. https://doi.org/10.2217/fca.14.62